School of Strength and Conditioning Training, Beijing Sport University, Beijing 100084, China.
College of Swimming, Beijing Sport University, Beijing 100084, China.
Nutrients. 2024 May 19;16(10):1529. doi: 10.3390/nu16101529.
(1) Background: Hydrogen (H) may be a potential therapeutic agent for managing Long COVID symptoms due to its antioxidant and anti-inflammatory properties. However, more scientific literature is needed to describe the effects of H administration on treating symptoms. A study aimed to investigate the impact of hydrogen-rich water (HRW) administration on the fatigue and dyspnea of Long-COVID patients for 14 consecutive days. (2) Methods: In this randomized, single-blind, placebo-controlled study, 55 participants were recruited, and 23 of them were excluded. A total of 32 eligible participants were randomized into a hydrogen-rich water (HRW) group ( = 16) and a placebo water (PW) group ( = 16) in which they were instructed to consume hydrogen-rich water or placebo water for 14 days, respectively. The participants completed the Fatigue Severity Scale (FSS), Six-Minute Walk Test (6MWT), 30 s Chair Stand Test (30s-CST), Modified Medical Research Council Dyspnea Rating Scale (mMRC), Pittsburgh Sleep Quality Index (PSQI), and depression anxiety stress scale (DASS-21) before and after the intervention. A linear mixed-effects model was used to analyze the effects of HRW. Cohen's d values were used to assess the effect size when significance was observed. The mean change with 95% confidence intervals (95% CI) was also reported. (3) Results: The effects of HRW on lowering FSS scores ( = 0.046, [95% CI = -20.607, -0.198, d = 0.696] and improving total distance in the 6WMT ( < 0.001, [95% CI = 41.972, 61.891], d = 1.010), total time for the 30s-CST ( = 0.002, [95% CI = 1.570, 6.314], d = 1.190), and PSQI scores ( = 0.012, [95% CI = -5.169, 0.742], d = 1.274) compared to PW were of a significantly moderate effect size, while there was no significant difference in mMRC score ( = 0.556) or DASS-21 score ( > 0.143). (4) Conclusions: This study demonstrates that HRW might be an effective strategy for alleviating fatigue and improving cardiorespiratory endurance, musculoskeletal function, and sleep quality. Still, it does not ameliorate dyspnea among Long-COVID patients.
(1)背景:由于具有抗氧化和抗炎特性,氢气(H)可能是管理长新冠症状的潜在治疗剂。然而,需要更多的科学文献来描述 H 给药对治疗症状的影响。一项研究旨在调查连续 14 天给氢水(HRW)对长新冠患者疲劳和呼吸困难的影响。
(2)方法:在这项随机、单盲、安慰剂对照研究中,招募了 55 名参与者,其中 23 名被排除在外。共有 32 名符合条件的参与者被随机分为富氢水(HRW)组(n=16)和安慰剂水(PW)组(n=16),他们分别被指示连续 14 天饮用富氢水或安慰剂水。参与者在干预前后完成疲劳严重程度量表(FSS)、六分钟步行测试(6MWT)、30 秒椅子站立测试(30s-CST)、改良医学研究委员会呼吸困难评分量表(mMRC)、匹兹堡睡眠质量指数(PSQI)和抑郁焦虑压力量表(DASS-21)。采用线性混合效应模型分析 HRW 的影响。当观察到显著性时,使用 Cohen's d 值来评估效应大小。还报告了平均变化和 95%置信区间(95%CI)。
(3)结果:HRW 对降低 FSS 评分(=0.046,[95%CI=-20.607,-0.198,d=0.696])和提高 6MWT 总距离(<0.001,[95%CI=41.972,61.891],d=1.010)、30s-CST 总时间(=0.002,[95%CI=1.570,6.314],d=1.190)和 PSQI 评分(=0.012,[95%CI=-5.169,0.742],d=1.274)的效果具有显著的中等效应大小,而 mMRC 评分(=0.556)或 DASS-21 评分(>0.143)无显著差异。
(4)结论:本研究表明,HRW 可能是一种缓解疲劳和改善心肺耐力、肌肉骨骼功能和睡眠质量的有效策略。然而,它并不能改善长新冠患者的呼吸困难。